Description
Act Now – Be Prepared for Tomorrow’s IVD Market
Don’t miss your chance to leverage Kalorama Information’s expert insights. Equip your business with the knowledge to anticipate changes, optimize product development, and maximize your strategies in the dynamic IVD landscape.
Ready to take action? Purchase the IVD Test Procedure Volumes, 2024-2029 report today and secure your competitive advantage in this billion-dollar industry.
Abstract
Kalorama Information’s IVD Test Procedure Volumes, 2024-2029 report provides a deep dive into the global trends shaping in vitro diagnostic (IVD) procedural volumes. Designed to complement Kalorama’s comprehensive market analysis in The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this essential report delivers actionable data on the growth, challenges, and emerging opportunities in the IVD space.
As a rapidly evolving market, the IVD landscape in 2024 is set to thrive, driven by new technologies, evolving healthcare spending, and a surge in demand for precision diagnostics. Our report not only identifies the most significant procedural segments but also breaks down the impact of ongoing innovations.
With this detailed market research, you can stay ahead of industry developments and make informed business decisions. Whether you are looking to expand your product portfolio, explore new market segments, or refine your strategic approach, IVD Test Procedure Volumes, 2024-2029 offers the data and insights you need to succeed.
Why Choose This Report?
- Comprehensive Market Data
Gain an in-depth understanding of IVD procedural volumes by type, region, and country. From self-testing and professional point-of-care (POC) to clinical chemistry, hematology, and beyond—this report covers it all.
- Unmatched Insights into Growth Opportunities
Identify high-growth segments by exploring emerging markets and the potential of precision medicine applications.
- Forward-Looking Analysis
Understand the trends impacting the IVD market, including shifts in regulatory landscapes, new product developments, and changing disease profiles. This report provides a comprehensive forecast from 2024 to 2029.
- Strategic Guidance for Industry Players
Discover how market dynamics, healthcare system trends, and cost pressures are shaping the future of IVD. Use these insights to develop strategies for product positioning, market entry, and growth.
Scope & Methodology
The report includes:
- Global IVD Procedure Volumes by type, covering self and professional POC, clinical chemistry, immunoassay, molecular diagnostics, hematology, coagulation, microbiology, blood banking, and histology/cytology.
- Regional and Country-Specific Data for IVD procedures and their projected growth rates.
- Cost Analysis of various IVD tests to evaluate profitability and potential revenue streams.
Table of Contents
Chapter One: Executive Summary
IVD Procedure Volume Estimate and Forecast
- Figure 1-1: Global IVD Procedure Volumes, 2024 and 2029 (in millions # volume)
Scope & Methodology
About Kalorama Information
Chapter Two: Introduction
Overview
Industry Trends
- Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
- Figure 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2024-2029 (in millions # volume; $ million)
COVID-19
Demographic Trends
Global Population and Aging
- Figure 2-2: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
- Figure 2-3: Global Population Distribution, 2022
- Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 (Australia; Brazil; Canada; China; China, Hong Kong SAR; France; Germany; India; Italy; Japan; Mexico; Saudi Arabia; Singapore; South Africa; Spain; Turkey; United Kingdom; United States; World)
Workforce Reduction
- Table 2-3: Age Under 15 and Over 65, by Continent, 2020 (Africa, Asia, Europe, Latin America/Caribbean, North America, Oceania)
Increase in Chronic Diseases
- Figure 2-4: Leading Causes of Death Globally, by Number of Deaths, 2021 (in millions)
Personalized Medicine
New Infectious Disease Threats
- Table 2-4: Selected Companies Marketing Products Addressing Emerging Infectious Disease Threats
Tickborne Diseases (TBDs)
Zika
Chagas
Dengue
Ebola
Chikungunya
Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
Marburg
SARS-CoV-2 (COVID-19)
Monkeypox
- Table 2-5: Selected FDA EUAs for Molecular Diagnostic Tests for Monkeypox
Emerging and Emerged Markets
- Table 2-6: Market Potential, by Total Population and Percent Urban, 2023 (population in million) (Brazil; Canada; Chile; China; Colombia; Egypt; India; Malaysia; Mexico; Peru; Poland; Russia; South Africa; South Korea; Saudi Arabia; Turkey; Ukraine; United States; Vietnam)
Chapter Three: IVD Testing Segments
IVD Testing Trends
- Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-2: IVD Procedural Volume including Blood Glucose Tests, by Item, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-3: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-4: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2024-2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-5: IVD Procedural Volume excluding Blood Glucose Tests, 2024 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-6: IVD Procedural Volume excluding Blood Glucose Tests, 2029 (millions) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-7: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-8: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Segment Growth Projections
POC Testing
- Table 3-5: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
- Figure 3-9: POC Testing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million) (POC Professional Tests; POC Self Testing)
Clinical Chemistry
- Table 3-6: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-10: Clinical Chemistry: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Immunoassays
- Table 3-7: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-11: Immunoassays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Mass Spectrometry (Immuno)
- Table 3-8: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-12: Mass Spectrometry (Immuno): IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Molecular Assays
- Table 3-9: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-13: Molecular Assays: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Hematology
- Table 3-10: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-14: Hematology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Coagulation
- Table 3-11: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-15: Coagulation: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Conventional Microbiology
- Table 3-12: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-16: Conventional Microbiology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Blood Grouping/Typing
- Table 3-13: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-17: Blood Grouping/Typing: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Histology/Cytology
- Table 3-14: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
- Figure 3-18: Histology/Cytology: IVD Procedural Volume and IVD Product Sales excluding Blood Glucose Tests, 2024-2029 (in millions # volume) ($ million)
Segment Product Sales
- Table 3-15: IVD Product Sales including Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-19: IVD Product Sales including Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-20: IVD Product Sales including Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Table 3-16: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-21: IVD Product Sales including Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-22: IVD Product Sales including Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Table 3-17: IVD Product Sales excluding Blood Glucose Tests, 2024-2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-23: IVD Product Sales excluding Blood Glucose Tests, 2024 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-24: IVD Product Sales excluding Blood Glucose Tests, 2029 ($ million) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Table 3-18: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024-2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-25: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2024 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
- Figure 3-26: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2029 (%) (Blood Grouping/Typing; Clinical Chemistry; Coagulation; Conventional Microbiology; Hematology; Histology/Cytology; Immunoassays; Mass Spectrometry [Immuno]; Mass Spectrometry [Micro]; Molecular; POC Professional Tests; POC Self Testing)
Chapter Four: Global IVD Markets
General
- Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central, & South America; Middle East; North America [United States; Canada]; Western Europe)
- Figure 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2024-2029 (millions) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
- Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024-2029 (%) (Africa; Asia/Pacific [China, Japan, Other Countries & Territories]; Eastern Europe; Mexico, Central & South America; Middle East; North America [United States; Canada]; Western Europe)
- Figure 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2024 (%) (Africa; Asia/Pacific; Eastern Europe; Mexico, Central & South America; Middle East; North America; Western Europe)
North America
- Table 4-3: North America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (Canada, United States)
- Figure 4-3: North America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions) (Canada, United States)
United States
Canada
Mexico, Central & South America
- Table 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions)
- Figure 4-4: Mexico, Central & South America IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
Brazil
Mexico
Other Central & South America
- Argentina
- Chile
- Colombia
- Peru
- Venezuela
- All Other Countries & Territories
Western Europe
- Table 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
- Figure 4-5: Western Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
France
Germany
Italy
Spain
United Kingdom
Other Western Europe
- Austria
- Belgium
- Denmark
- Finland
- Greece
- Ireland
- Norway
- Netherlands
- Portugal
- Sweden
- Switzerland
- All Other Countries & Territories
Eastern Europe
- Table 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
- Figure 4-6: Eastern Europe IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
Russia
Other Eastern Europe
- Czech Republic
- Hungary
- Poland
- Romania
- Ukraine
- All Other Countries
Asia/Pacific
- Table 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%) (China, Japan, Other Countries & Territories)
- Figure 4-7: Asia/Pacific IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
China
Japan
Other Asian Countries and Territories
- Australia
- Hong Kong
- India
- Indonesia
- Malaysia
- Pakistan
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- New Zealand
- All Other Countries & Territories
Middle East
- Table 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
- Figure 4-8: Middle East IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
Turkey
Other Middle East
- Iran
- Iraq
- Israel
- Saudi Arabia
- United Arab Emirates
- All Other Countries
Africa
- Table 4-9: Africa IVD Procedural Volume including Blood Glucose Tests and Market Share, 2024-2029 (millions) (%)
- Figure 4-9: Africa IVD Procedural Volume including Blood Glucose Tests, 2024-2029 (millions)
- Nigeria
- South Africa
- All Other Countries & Territories
Chapter Five: Point-of-Care (POC) Procedures
Global POC Procedure Volume by Test Type
- Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2024-2029
- Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2024-2029
- Figure 5-1: Regional POC Procedure Volumes excluding blood glucose tests, 2024 (Europe, Japan, United States, Rest of World)
POC Self Tests
- Table 5-3: POC Self-Test Procedural Volume, by Type, 2024-2029 (millions) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
Traditional Blood Glucose Monitoring Activities
Continuous Blood Glucose Monitoring
Pregnancy and Fertility Testing
Coagulation Testing
Fecal Occult Blood Testing
Drugs of Abuse Testing
- Pylori Testing
HIV Testing
Infectious Disease
Cholesterol Testing
POC Urinalysis Testing
Other POC Self-Testing
POC Self-Testing Product Sales
- Table 5-4: POC Self-Test Product Sales, by Type, 2024-2029 ($ million) (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
Pricing Trends
- Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2024-2029 (Cholesterol; Coagulation; Drugs of Abuse; Fecal Occult Blood; Glucose, Continuous; Glucose, Self; H. pylori; HIV; Infectious Disease [incl. COVID-19]; Pregnancy; Urinalysis; Other [TSH, Allergy, Autoimmune, etc.])
POC Professional Testing
- Table 5-6: POC Professional Procedural Volume, by Type, 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
POC Professional Blood Glucose Testing Procedures
POC Professional Critical Care Testing
POC Fertility Testing
POC Professional Infectious Disease Testing
POC Professional Cardiac Marker Testing
POC Professional Cholesterol/Lipid Testing
POC Professional Coagulation Testing
POC Professional HbA1C Testing
POC Professional Hematology Testing
POC Professional Fecal Occult Blood Screening
POC Professional Drugs of Abuse Testing
POC Professional Urinalysis Testing
Other POC Professional Testing
POC IVD Product Sales
- Table 5-7: POC Professional IVD Product Sales, by Type, 2024-2029 ($ million) (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
Pricing Trends
- Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2024-2029 (Cardiac Markers; Cholesterol; Coagulation; Critical Care POC; Drugs of Abuse; Fecal Occult Blood; Fertility; Glucose; HbA1c POC; Hematology; Infectious Diseases; Urine; Others)
Chapter Six: Clinical Chemistry Procedures
- Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2024-2029 (Blood Gas Analysis, General Chemistry, Urinalysis)
- Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
Types of Tests
General Chemistry
- Enzymes
- Glucose
- Lipids
- Proteins
- Other Compounds
Blood Gases & Electrolytes
Urinalysis
Global Sales of Clinical Chemistry Products
- Table 6-2: Clinical Chemistry Product Sales, by Type, 2024-2029 ($ million) (Blood Gas Analysis; General Chemistry; Urinalysis)
Pricing Trends
- Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2024-2029 (Blood Gas Analysis; General Chemistry; Urinalysis)
Chapter Seven: Immunoassay Procedures
Technologies
Labeling Techniques
Enzyme Immunoassays
Fluorescence Polarization Immunoassays (FPIAs)
Radioimmunoassays (RIAs)
- Table 7-1: Immunoassay Procedural Volume, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
- Figure 7-1: Regional Immunoassay Procedure Volumes, 2024
Testing Procedures & Product Sales
- Table 7-2: Immunoassay Product Sales, by Type, 2024-2029 ($ million) (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
Cardiac Markers
Tumor Markers
Autoimmune Conditions
Allergy Conditions
Thyroid Conditions
Proteins
Anemia
Fertility Testing
Therapeutic Drug Monitoring
Vitamin D
Diabetes/HbA1c
Drugs of Abuse
Infectious Diseases
- Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2024-2029 (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
- Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (HAI; Hepatitis; HIV; Resp; STD; ToRCH; Other)
Instruments
Pricing Trends
- Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2024-2029 (Allergy; Anemia; Autoimmune; Cardiac Markers; Diabetes/HbA1c; Fertility; Infectious Disease; Mass Spectrometry; Proteins; Therapeutic Drugs; Thyroid; Tox/Drug of Abuse; Tumor Markers; Vitamin D; Others)
Chapter Eight: Molecular Testing Procedures
- Table 8-1: Molecular Assay Procedural Volume, by Type, 2024-2029 (millions) (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
- Figure 8-1: Regional Molecular Assay Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
Types of Tests
Testing Technologies
Infectious Diseases
- Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2024-2029 (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
Blood Screening
Cancer
Transplant Matching
Thrombophilia SNPs
Inherited Diseases
Other Molecular Tests
Prenatal
Global Sales of Molecular IVD Products
- Table 8-3: Molecular Assay Product Sales, by Type, 2024-2029 ($ million) (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
- Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2024-2029 ($ million) (COVID; GC/Chlamydia; HAI; Hepatitis; HIV; Mycobacteria/TB; Respiratory non-COVID; Other)
Pricing Trends
- Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2024-2029 (Molecular – Other; Molecular Assays – Oncology; Molecular Blood Bank; Molecular Histology – Non Cancer; Molecular Histology – Cancer; Molecular HPV; Molecular Infectious Disease; Molecular Inherited Diseases; Molecular PT/INR [thrombophilia SNP tests]; Molecular Transplant Testing [HLA] Tissue Typing; Prenatal)
Chapter Nine: Laboratory-Based Hematology Procedures
- Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2024-2029 (Complete Blood Count; Other Hematology Tests)
- Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2024 (Asia Pacific, Europe, United States, Rest of World)
Types of Tests
Global Sales of Hematology Products
- Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2024-2029 ($ million) (Complete Blood Count; Other Hematology Tests)
Pricing Trends
- Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2024-2029 (Complete Blood Count, Other Hematology Tests)
Chapter Ten: Coagulation Testing Procedures
- Table 10-1: Coagulation Procedural Volume, 2024-2029 (D-dimer, PT/INR)
- Figure 10-1: US/ROW Coagulation Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
Types of Tests
Global Sales of Coagulation Products
- Table 10-2: Coagulation Product Sales, 2024-2029 ($ million) (D-dimer, PT/INR)
Pricing Trends
- Table 10-3: Coagulation $ Products per Procedure, 2024-2029 (D-dimer, PT/INR)
Chapter Eleven: Microbiology Procedures
- Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2024-2029 (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
- Figure 11-1: Regional Microbiology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
Types of Tests
ID/AST Automated Panels & Reagents
Manual Panels & Reagents
Blood Culture
Chromogenic Media
Rapid Microbiological Tests
Mass Spectrometry
Global Sales of Conventional IVD Microbiology Products
ID/AST Panels & Reagents
Blood Culture
Chromogenic Media
Rapid Microbiological Tests
Mass Spectrometry
- Table 11-2: Conventional Microbiology Product Sales, by Type, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
Pricing Trends
- Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2024-2029
- (Blood Culture; Chromogenic Media; ID/AST Automated; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
Chapter Twelve: Blood Grouping/Typing Procedures
- Table 12-1: Blood Grouping/Typing Procedure Volumes, 2024-2029
- Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
Types of Tests
Blood Grouping/Typing Product Sales
- Table 12-2: Blood Grouping/Typing Product Sales, 2024-2029 ($ million)
Pricing Trends
- Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2024-2029
Chapter Thirteen: Histology/Cytology Procedures
- Table 13-1: Histology/Cytology Procedural Volume, by Type, 2024-2029 (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
- Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2024 (Asia Pacific, Europe, North America, Rest of World)
Types of Tests
Immunohistochemistry Tests
In Situ Hybridization Tests
Pap Tests
Traditional Non-Pap Stains
Circulating Tumor Cells
Flow Cytometry
Histology/Cytology IVD Product Sales
- Table 13-2: Histology/Cytology Product Sales, by Type, 2024-2029 ($ million) (CTCs; Flow Cytometry; Immunohistochemistry; In situ Hybridization; Pap Tests; Traditional non-Pap Stains)
Pricing Trends
- Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2024-2029
Chapter Fourteen: Company Profiles
- Table 14-1: Revenues of Selected Top 20 IVD Companies, 2023 and estimated 2024 ($ million) (Abbott Diagnostics; Agilent; Becton Dickinson; bioMérieux; Bio-Rad Laboratories; Bruker – CALID; Danaher; Dexcom; DiaSorin; Exact Sciences; Hologic; Illumina; Natera; QuidelOrtho; Revvity; Roche Diagnostics; Siemens Healthineers; Sysmex Corporation; Thermo Fisher Scientific; Werfen)
Abbott Diagnostics
Recent Revenue History
- Table 14-2: Abbott Diagnostic Revenues, 2017-2023 (million $)
Core Lab
Hematology
Blood Banking
Infectious Diseases – Molecular
Diabetes
HIV Point of Care
i-STAT Business
COVID-19
Agilent Technologies
Recent Revenue History
- Table 14-3: Agilent Revenues, 2017-2023 (million $)
Agilent in Genomics
Cytogenetic Analysis
Sequencing
Flow Cytometry
Companion Diagnostics – Dako
COVID-19
Becton, Dickinson and Company (BD)
Recent Revenue History
- Table 14-4: BD Diagnostic Revenues, 2017-2023 (million $) FYE Sept 30
Cytology
Molecular Microbiology
Traditional Microbiology – ID/AST
Blood Culture
Hospital Acquired Infections
Blood Collection
Mass Spectrometry
COVID-19
bioMérieux Inc.
Recent Revenue History
- Table 14-5: bioMérieux IVD Revenues, 2017-2023 (million $)
Traditional Microbiology
Blood Culture
Immunoassays
Mass Spectrometry
BioFire Diagnostics Business
COVID-19
Bio-Rad Laboratories, Inc.
Recent Revenue History
- Table 14-6: Bio-Rad Diagnostics Revenues, 2017-2023 (million $)
Blood Bank
Immunoassays
COVID-19
Bruker Corporation
Recent Revenue History
- Table 14-7: Bruker Revenue History Product Revenue, 2017-2023 ($ million)
Acquisitions and Collaborations
Mass Spectrometry
Microbiology
Molecular PCR
COVID-19
Danaher Corporation
Recent Revenue History
- Table 14-8: Danaher Global IVD Diagnostic Sales, 2017-2023 (million $)
Dexcom
Recent Revenue History
- Table 14-9: Dexcom IVD Diagnostic Sales, 2017-2023 (million $)
DiaSorin
Recent Revenue History
- Table 14-10: DiaSorin Revenues, 2017-2023 (million $)
Immunoassays
Molecular
COVID-19
Exact Sciences
Recent Revenue History
- Table 14-11: Exact Sciences Revenues, 2017-2023 (million $)
COVID-19
Hologic, Inc.
Recent Revenue History
- Table 14-12: Hologic Revenues, 2017-2023 (million $)
PANTHER Molecular System
HIV Testing
Sexually Transmitted Infections
Infectious Diseases
Cytology
COVID-19
Illumina
Recent Revenue History
- Table 14-13: Illumina Diagnostics Revenues, 2017-2023 (million $)
COVID-19
Instrument Laboratory/ Werfen
Expansion
Coagulation
Acute Care
Natera
Recent Revenue History
- Table 14-14: Natera Revenue History 2017-2023 ($ million)
Prenatal Paternity Testing
QuidelOrtho Corporation
Recent Revenue History
- Table 14-15: QuidelOrtho Revenue History 2018-2023 ($ million)
Immunoassays
Rapid Immunoassays
The Solana Business
Molecular – Savanna
Blood Bank
COVID-19
Revvity
- Table 14-16: Revvity Revenue History 2021-2023 ($ million, estimated)
Roche Diagnostics
Recent Revenue History
- Table 14-17: Roche Diagnostics IVD Revenues, 2017-2023 (million $)
Hematology
Core Lab
Immunoassays
HIV
Core Molecular
Digital PCR
Diabetes Care
Coagulation
cobas Liat System – POC
HPV
Blood Bank
Transplant Medicine
Cancer Companion Testing
COVID-19
Siemens Healthineers (Siemens)
Recent Revenue History
- Table 14-18: Siemens Healthineers IVD Revenues, 2017-2023 (million $)
Immunoassays
Hematology
Molecular
Acute Care – POC
COVID-19
Sysmex Corporation
Recent Revenue History
- Table 14-19: Sysmex IVD Revenues 2018-2023 (million $) FY March 31
Hematology
Coagulation
Urinalysis
Immunoassays
Precision Medicine / Companion Test Diagnostics
Oncology
COVID-19
Thermo Fisher Scientific Inc.
Recent Revenue History
- Table 14-20: Thermo Fischer IVD Revenues, 2017-2023 (million $)
Immunoassays
Microbiology
Next Generation Sequencing
Molecular and qPCR
Mass Spectrometry
COVID-19
Werfen
Recent Revenue History
- Table 14-21: Werfen IVD Revenues, 2017-2023 (million $)
Hematology and Coagulation
Autoimmunity
